The ␤-lactamase inhibitor avibactam (NXL104) displays potent inhibition of both class A and C enzymes. The in vitro antibacterial activity of the combination ceftazidime-avibactam was evaluated against a clinical panel of Pseudomonas aeruginosa isolates. Avibactam offered efficient protection from hydrolysis since 94% of isolates were susceptible to ceftazidime when combined with 4 g/ml avibactam, compared with 65% susceptible to ceftazidime alone. Ceftazidime-avibactam also demonstrated better antipseudomonal activity than imipenem (82% susceptibility), a common reference treatment.
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P
seudomonas aeruginosa is a major opportunistic pathogen frequently involved in hospital-acquired infections that may be resistant to many classes of antimicrobial agents. The expression of the naturally occurring chromosomal AmpC ␤-lactamase, as well as acquired extended-spectrum ␤-lactamases (ESBLs), strongly limits the susceptibility of P. aeruginosa isolates to penicillins, such as piperacillin, and cephalosporins, such as ceftazidime. In addition, most of these enzymes are only poorly inhibited by the ␤-lactamase inhibitors clavulanic acid and tazobactam. Resistance to imipenem is also common and is frequently associated with the loss of functional OprD outer membrane protein and, less frequently, with production of metallo-␤-lactamases or specific carbapenemase class A enzymes, such as GES or KPC variants (3). Infections caused by P. aeruginosa represent a serious therapeutic challenge, with significant morbidity and mortality (8) and high rates of resistance to ␤-lactams, aminoglycosides, and fluoroquinolones. Due to its ability to acquire and coregulate multiple resistance mechanisms, multidrug resistance is relatively common in P. aeruginosa. While carbapenems are considered the treatment of choice for severe P. aeruginosa infections, colistin is currently the only antibacterial agent active in vitro against the most highly resistant strains (6) .
Avibactam is a novel non-␤-lactam inhibitor of ␤-lactamases that is currently in clinical development with both ceftazidime and ceftaroline. It displays a broad-spectrum inhibitory profile against clinically relevant enzymes belonging to Ambler classes A and C (1, 7). Avibactam has virtually no intrinsic antibacterial activity, but it efficiently protects ␤-lactams from hydrolysis in a variety of class A-and class C-producing strains, including ESBL and KPC producers, as well as AmpC-overexpressing strains, many of which are poorly inhibited by clavulanic acid and tazobactam. Avibactam was shown to restore ceftazidime activity against a series of selected P. aeruginosa strains with identified ␤-lactamases (4). The aim of this study was to evaluate the in vitro antibacterial activity of the combination ceftazidime-avibactam compared with those of ceftazidime, imipenem, aztreonam, and piperacillin, alone or in combination with the commercially available inhibitors clavulanate, sulbactam, and tazobactam, against a panel of unselected, clinically isolated P. aeruginosa strains, in order to give an indication of the utility of the combination in a clinical setting.
A series of 126 P. aeruginosa strains were collected as consecutive clinical isolates in a South Paris hospital (Hôpital de KremlinBicêtre, France) between December 2006 and April 2007. They were isolated from patients suffering from serious infections with various comorbidities. MIC determination was performed using the guidelines of the Clinical and Laboratory Standards Institute for antimicrobial susceptibility testing and for categorical interpretations (2). Avibactam, clavulanic acid, and tazobactam were used at a fixed concentration of 4 g/ml with variable concentrations of ceftazidime, aztreonam, imipenem, or piperacillin, respectively; the breakpoints considered for the combinations were the ones defined for antibiotics alone.
As shown in Table 1 , the susceptibility of the isolates to ␤-lactam agents was as follows: 48% were susceptible to aztreonam, 65% were susceptible to ceftazidime, 75% were susceptible to piperacillin-tazobactam, and 86% were susceptible to imipenem. These proportions were consistent with those measured in a recent study in European countries, except for ceftazidime, to which isolates exhibited higher resistance rates here (6). Avibactam was effective in lowering MICs for all the ␤-lactams tested, but offered different levels of protection from hydrolysis. While aztreonam-avibactam showed very modest activity, with only 64% of isolates in the susceptible range, piperacillin-avibactam and imipenem-avibactam were active against 94% and 98%, respectively, of the strain panel. Avibactam also potently restored ceftazidime activity, with 94% of isolates susceptible to the combination in this clinical panel. Compared with marketed ␤-lactams, ceftazidime-avibactam was the most potent agent, as illustrated in Fig. 1 by the percentage of cumulative frequency of susceptible P. aeruginosa strains. Table 1 shows the MIC 50 and MIC 90 values of the ␤-lactam antibiotics alone and in combination with different ␤-lactamase inhibitors. As a single agent, imipenem was the most potent, with a MIC 50 of 2 g/ml and a MIC 90 of 16 g/ml; when combined with avibactam, imipenem showed the most potent activity, with a MIC 90 value of 2 g/ml. The MIC 50 and MIC 90 values were also lowered for a ceftazidime-avibactam combination (4 and 8 g/ml) compared to ceftazidime alone (8 and 64 g/ml), while the other ␤-lactamase inhibitors were only poorly active when combined with ceftazidime, with MIC 50 and MIC 90 values similar to those of ceftazidime alone (8 and 64 g/ml for ceftazidime-clavulanic acid and 4 and 32 g/ml for ceftazidime-tazobactam).
Genetic relatedness of isolates was evaluated by analysis of chromosomal DNA restriction patterns after SpeI restriction endonuclease digestion, pulsed-field gel electrophoresis and (PFGE) separation of the DNA fragments. The DNA restriction patterns of the isolates were then compared with one another to determine their relatedness; interpretation of DNA restriction patterns and PFGE type assignment were performed according to established guidelines (9) . The analysis was performed on the 44 strains showing an intermediate or resistant profile to ceftazidime (MIC values, Ն16 g/ml). Twenty-three of the strains had unique PFGE profiles, and 21 strains were scattered in 6 different pulsotypes. A total of 29 different pulsotypes were identified, thus demonstrating a high clonal diversity in those 44 ceftazidime-nonsusceptible strains (data not shown). In addition, the eight strains with a phenotype resistant or intermediate to ceftazidime in the presence of avibactam all showed different pulsotypes.
The eight strains showing an intermediate or resistant phenotype to the ceftazidime-avibactam combination were characterized according to the presence of the main ␤-lactamase subgroups. Table 2 shows the MIC values of these 8 strains: for 5 c Susceptible/resistant phenotype interpretations are as follows: for single agents and for combinations, Յ8/Ն32 g/ml for ceftazidime and aztreonam, Յ4/Ն16 g/ml for imipenem, and Յ64/Ն128 g/ml for piperacillin. As of yet, there are no breakpoint criteria for any of the avibactam combinations; the breakpoints considered for the combinations with a ␤-lactamase inhibitor were the ones defined for antibiotics alone. The ␤-lactamase inhibitors tested were added at 4 g/ml. d NA, not applicable. isolates, the addition of avibactam partially restored ceftazidime activity, with MIC values reduced 4-to Ͼ8-fold to 16 g/ml and 32 g/ml compared with ceftazidime alone; 7 out of 8 strains were resistant to piperacillin-tazobactam, and 3 of these were also nonsusceptible to imipenem. Gene detection was achieved by PCR amplification using the appropriate primers for detection of the most common bla gene families: class A TEM, SHV, VEB, PER, GES, CARB, CTX-M, and KPC; class B IMP and VIM; and class D OXA-1, -2, -5, -9, -10, -20, -23, -24, -46, -48, -51, and -58 families.
Only one strain showed acquired ␤-lactamases, CARB-PSE and OXA-5 ( Table 2) , both of which normally have poor cephalosporinase activity when expressed alone. In the absence of a specific ␤-lactamase enzyme, the mechanism leading to ␤-lactam resistance in P. aeruginosa is usually considered multifactorial: upregulation of chromosomal AmpC activity, reduced porin expression, and augmented antibiotic efflux have all been defined as contributory factors (5) . P. aeruginosa is one of the most common pathogens implicated in serious nosocomial infections, and resistance to the commonly used agents has become more prevalent. Resistance to antipseudomonal cephalosporins is mainly due to overexpression of the chromosomally encoded AmpC ␤-lactamase and occasionally to acquisition of extended-spectrum ␤-lactamases (3). It was previously shown in P. aeruginosa transconjugants and clinical isolates with defined AmpC mutations or acquired ␤-lactamases that avibactam can overcome ceftazidime resistance (4) . Furthermore, in a study with 470 Canadian P. aeruginosa clinical strains, a 4-fold reduction of ceftazidime MIC 90 was shown when combined with avibactam (10) . These data are consistent with the results of the present study with French P. aeruginosa isolates. As a potent inhibitor of AmpC hydrolytic activity, avibactam, when combined with an antipseudomonal ␤-lactam, may be appropriate as empirical therapy in hospitals where AmpC overexpression is prevalent.
